This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Centre National De La Recherche Scientifique, Helmholtz-Zentrum Fur Infektionsforschung Gmbh. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2026
Title: Sakonwan Kuhaudomlarp: Innovator in Biofilm Inhibition
Introduction
Sakonwan Kuhaudomlarp is a notable inventor based in Grenoble, France. He has made significant contributions to the field of biofilm research, particularly through his innovative patent related to bivalent LECA inhibitors. His work focuses on addressing the challenges posed by biofilm formation, which can complicate infections and treatment methods.
Latest Patents
Sakonwan holds a patent for "Bivalent LECA inhibitors targeting biofilm formation." This invention pertains to divalent compounds that bind to LecA, which are useful in blocking biofilm formation. The patent also encompasses pharmaceutical compositions that include these compounds, along with therapeutic methods for treating infections in subjects. Additionally, the invention relates to imaging infections, such as biofilms, using these divalent compounds.
Career Highlights
Throughout his career, Sakonwan has worked with prestigious institutions, including the Centre National de la Recherche Scientifique and Helmholtz-Zentrum für Infektionsforschung GmbH. His experience in these organizations has allowed him to advance his research and contribute to the scientific community.
Collaborations
Sakonwan has collaborated with notable colleagues, including Eva Záhorská and Alexander Titz. These partnerships have enriched his research and fostered innovation in the field of biofilm inhibition.
Conclusion
Sakonwan Kuhaudomlarp is a pioneering inventor whose work on bivalent LECA inhibitors has the potential to transform the treatment of infections related to biofilm formation. His contributions to science and collaboration with esteemed institutions highlight his commitment to advancing medical research.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile